Luboš Petruželka
- Oncology top 1%
- Pulmonary and Respiratory Medicine top 1%
- Molecular Biology top 10%
- Cancer Research top 2%
- Genetics top 5%
- Co-authors
- Petr ZatloukalFilip JankúLibor HavelMilada ZemanováA KubíkGuy JérusalemР. Ш. ХасановRoberto Torres
- Topics
- Cancer Treatment and Pharmacology (39 papers)Colorectal Cancer Treatments and Studies (26 papers)HER2/EGFR in Cancer Research (24 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaPLoS ONE
- Partner nations
- CzechiaPolandUnited States
In The Last Decade
Luboš Petruželka
163 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Oncology 2.0k
- Pulmonary and Respiratory Medicine 1.6k
- Molecular Biology 872
- Cancer Research 771
- Genetics 542
Countries citing papers authored by Luboš Petruželka
This map shows the geographic impact of Luboš Petruželka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luboš Petruželka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luboš Petruželka more than expected).
Fields of papers citing papers by Luboš Petruželka
This network shows the impact of papers produced by Luboš Petruželka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luboš Petruželka. The network helps show where Luboš Petruželka may publish in the future.
Co-authorship network of co-authors of Luboš Petruželka
This figure shows the co-authorship network connecting the top 25 collaborators of Luboš Petruželka. A scholar is included among the top collaborators of Luboš Petruželka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luboš Petruželka. Luboš Petruželka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 5 | |
| 3 | 1 | |
| 4 | 4 | |
| 5 | 2 | |
| 6 | 8 | |
| 7 | LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLCbreakdown → | 67 |
| 8 | 0 | |
| 9 | Review of tumor infiltrating lymphocytes assessment in breast cancer in routine diagnostic practice. | 0 |
| 10 | 6 | |
| 11 | Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients | 1 |
| 12 | 2 | |
| 13 | 9 | |
| 14 | 33 | |
| 15 | 8 | |
| 16 | 5 | |
| 17 | Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. | 6 |
| 18 | 5 | |
| 19 | 3 | |
| 20 | Lung cancer risk among nonsmoking women in relation to diet and physical activity. | 30 |
About Luboš Petruželka
Luboš Petruželka is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 181 papers that have together received 3.8k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (39 papers), Colorectal Cancer Treatments and Studies (26 papers) and HER2/EGFR in Cancer Research (24 papers). The work is most often cited by research in Oncology (2.0k citations), Cancer Research (771 citations) and Pulmonary and Respiratory Medicine (1.6k citations). Luboš Petruželka has collaborated with scholars based in Czechia, Poland and United States. Frequent co-authors include Petr Zatloukal, Filip Jankú, Libor Havel, Milada Zemanová, A Kubík, Guy Jérusalem, Р. Ш. Хасанов, Roberto Torres, Sally Garnett and Kelly Pendergrass. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.